’Reddit is built for this moment’ - Stock soars on crushed earnings
Sandra D. van der Vaart, the Executive Vice President and Chief Legal Officer of Labcorp Holdings Inc. (NYSE:LH), recently sold a significant portion of her shares in the company. According to a recent SEC filing, van der Vaart sold 1,314 shares of common stock on February 25, 2025, at a price of $251.30 per share. This transaction amounted to a total value of $330,208. Following the sale, van der Vaart retains ownership of 2,170.54 shares in the company. The sale comes as Labcorp’s stock trades near its 52-week high of $258.59, having delivered an 18% return over the past year. InvestingPro data shows management has been actively buying back shares, suggesting confidence in the company’s outlook. Labcorp Holdings, based in Burlington (NYSE:BURL), North Carolina, is a prominent player in the medical laboratories sector. With a market capitalization of $21 billion and an overall financial health score of GOOD according to InvestingPro, the company maintains a strong position in the Healthcare Providers & Services industry. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering this and 1,400+ other top US stocks.
In other recent news, Immutep (NASDAQ:IMMP) Limited has disclosed its financial results for the half-year period ended February 26, 2025, as part of its compliance with SEC regulations. While specific financial details were not provided in the summary, the full report is available in the SEC filing, offering insights into the company’s financial performance, including revenue and expenses. Investors can access this information through the SEC’s EDGAR database. Meanwhile, Labcorp has announced the clinical availability of Labcorp Plasma CompleteTM, a liquid biopsy test for genomic profiling in patients with advanced solid tumors. This test aims to aid oncologists in creating personalized treatment plans and has been validated for clinical accuracy. Additionally, Labcorp has expanded its credit facilities, increasing the limit from $300 million to $700 million, a move that suggests a proactive approach to managing its capital structure. Truist Securities and Jefferies have both raised their price targets for Labcorp, citing strong financial results and a promising outlook for 2025. Truist adjusted the target to $285, while Jefferies increased it to $290, both maintaining a Buy rating on the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.